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Abstract 
Background:  The disposition of a pharmaceutical compound within an organism, i.e. its Absorption, Distribution, 
Metabolism, Excretion, Toxicity (ADMET) properties and adverse effects, critically affects late stage failure of drug can-
didates and has led to the withdrawal of approved drugs. Computational methods are effective approaches to reduce 
the number of safety issues by analyzing possible links between chemical structures and ADMET or adverse effects, 
but this is limited by the size, quality, and heterogeneity of the data available from individual sources. Thus, large, 
clean and integrated databases of approved drug data, associated with fast and efficient predictive tools are desirable 
early in the drug discovery process.
Description:  We have built a relational database (IDAAPM) to integrate available approved drug data such as drug 
approval information, ADMET and adverse effects, chemical structures and molecular descriptors, targets, bioactivity 
and related references. The database has been coupled with a searchable web interface and modern data analytics 
platform (KNIME) to allow data access, data transformation, initial analysis and further predictive modeling. Data were 
extracted from FDA resources and supplemented from other publicly available databases. Currently, the database 
contains information regarding about 19,226 FDA approval applications for 31,815 products (small molecules and bio-
logics) with their approval history, 2505 active ingredients, together with as many ADMET properties, 1629 molecular 
structures, 2.5 million adverse effects and 36,963 experimental drug-target bioactivity data.
Conclusion: IDAAPM is a unique resource that, in a single relational database, provides detailed information on 
FDA approved drugs including their ADMET properties and adverse effects, the corresponding targets with bioactiv-
ity data, coupled with a data analytics platform. It can be used to perform basic to complex drug-target ADMET or 
adverse effects analysis and predictive modeling. IDAAPM is freely accessible at http://idaapm.helsinki.fi and can be 
exploited through a KNIME workflow connected to the database.
Keywords: FDA approved drugs, ADMET, Adverse effects, Targets, Database, Predictive modeling, Drug-target 
database, Data analysis
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Background
Absorption, Distribution, Metabolism, Excretion, Toxic-
ity (ADMET) properties and adverse effects are consid-
ered to be responsible for the late stage failure of many 
promising compounds as well as for the withdrawal of 
approved drug molecules. Despite considerable efforts 
to improve the pharmacokinetic profiles of small-mole-
cule drug candidates, overall attrition rates remain high 
mainly due to efficacy, safety issues, and selection of 
inappropriate drug targets [1–3].
Computational prediction of ADMET properties and 
adverse effects is an effective method to minimize the risk 
of late-stage attrition and reduce the number of safety 
issues. This method is now well established as a reliable 
and cost-effective approach to assist the drug discovery 
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process. Computational models are used to focus medici-
nal chemistry efforts into the suitable chemical space; to 
connect, use and extend experimental data; to minimize 
the number of compounds to be synthesized; as well as 
to obtain a favorable biochemical and/or physicochemi-
cal profile [4–12]. For example, multiple studies have 
explored the benefit of controlling the size, lipophilic-
ity and polarity properties of compounds in terms of 
reduced likelihood of attrition [4–8, 13–15].
Currently, a large amount of data is made available 
by the pharmaceutical industry and academic research 
groups that can be used for computational predictions. 
These data have been deposited in databases, among 
which the most well-established and freely accessi-
ble are DrugBank [16], ChEMBL [17], BindingDB [18], 
PubChem [19], PDB [20], PDBbind [21], GtoPdb [22], 
Therapeutic Target Database [23] and ChemIDPlus [24]. 
DrugBank integrates detailed chemical, pharmacological 
and pharmaceutical drug data with target information. 
ChEMBL contains the chemical structures and bioactiv-
ity data of compounds with drug-like properties. Bind-
ingDB and PDBbind provides ligand–target interaction 
experimental affinity data that are mainly collected from 
scientific literature and other auxiliary databases such 
as ChEMBL. GtoPdb (previously IUPHAR-DB) contains 
ligand information and special sections for receptors, ion 
channels, kinases and transporters. Therapeutic Target 
Database (TTD) provides information about the known 
and explored therapeutic protein and nucleic acid targets 
such as disease, pathway and drugs connected to each 
of these targets. ChemIDPlus focus more on molecu-
lar and structural information of compounds. The US 
food and drug administration (FDA) has two publicly 
available databases; Drugs@FDA [25] which is the main 
resource that provides FDA-approved drug information, 
and FAERS (FDA adverse event reporting system), which 
contains a collection of reported post-marketed adverse 
effects [26, 27].
Focused and integrated databases with predictive 
ADMET and adverse effects models have been developed 
to exploit this data. UCSF-FDA TransPortal [28] focus 
on interaction of drug molecules with transporters, lead-
ing to drug–drug interactions. For example, Sedykh et al. 
collected and published a large collection of transporter 
interaction data for small molecules focused on major 
human intestinal transporters with the aim of building 
predictive models [29]. Moda et al. [30] developed a data-
base, PK/DB associated with five in silico ADME models 
to predict human intestinal absorption, human oral bio-
availability, plasma protein binding, blood-brain barrier 
and water solubility. Kuhn et al. have developed a data-
base called SIDER [31], which contains adverse effects of 
drugs and their frequency, however, unlike FAERS which 
is a reporting system, SIDER extracts the causal relation 
from the drug label. In another recent study, Cheng and 
coworkers developed a meta-database of drug adverse 
effects, MetaADEDB, which includes the SIDER data 
[32].
Although these resources possess an already large 
amount of ADMET or adverse effects data, they all have 
different aims and contents. Consequently, they do not 
integrate additional related data (e.g. approval applica-
tion, affinity data, molecular descriptors, data references, 
adverse effects) and metadata required for in-depth pre-
dictive modeling analyses. It therefore requires tedious 
data preparation and cleaning to exploit these data for 
predictive modeling of ADMET properties or adverse 
effects. Therefore, a unified approved drugs information 
database, combined with fast and efficient predictive 
tools is desirable.
Here we describe IDAAPM, a publicly available data-
base of FDA approved drugs, which have been devel-
oped as a useful resource for computational analyses and 
modeling. IDAAPM aims to bridge the gap by provid-
ing, in a single resource, integrated detailed information 
on approved drugs (small molecules and biologics) such 
as FDA application data, structures, molecular descrip-
tors, ADMET properties and adverse effects, target and 
also related bioactivity data that are often missing in 
other comparable databases. This resource can be used 
to analyze relevant information across studies based on 
compound similarities and the chemical space associ-
ated with drug molecules. It would become possible to 
easily infer relationships among physicochemical proper-
ties and ADMET properties and adverse effects based on 
how new compounds overlap with the space of approved 
drugs and their targets for new compounds. IDAAPM is 
coupled with KNIME [33], a modern data analytics plat-
form to allow data access, data transformation, initial 
analysis, visualization and predictive modeling. KNIME 
platform implements a modular approach to workflow 
management and allows the flexibility to incorporate dif-
ferent tools and also create specialized workflows that are 
easy to use for automation.
Construction and content
Data source
Approved drugs (small molecule and biologics) applica-
tion information was collected from the FDA resource 
Drug@FDA. For each drug entry, the standard drug 
information was collected, including trade names, 
administration routes, dosage, and approval data. Simi-
larly, adverse effect reports for each drug were taken 
from FAERS, among them; patient data (demograph-
ics and administrative) and drug related data (name, 
indication, dosage, drug name, route of administration, 
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frequency). Adverse effects are reported using the 
“preferred terms” (PT) of the medical dictionary for 
regulatory activities (MedDRA) [34]. MedDRA has a 
hierarchical structure with five levels: system organ class 
(SOC), high level group, high level, PT and lowest level. 
FAERS data are entered in the system by health care pro-
fessionals and consumers, which can lead to errors and 
non-normalized data, thus forming substantial barriers 
for data integration for the purpose of data analysis. In 
IDAAPM, we have linked the PT to their corresponding 
26 SOC to solve typographical errors and the PT differ-
ence between MedDRA versions. This produces data 
ready for mining that are clean, normalized and aggre-
gated into fewer classes.
The two dimensional structure of the approved drugs, 
molecular descriptors and ADMET properties and 
adverse effects were collected from DrugBank and cross 
checked with PubChem, and ChemIDplus. Binding 
affinities and drug target data were collected from Bind-
ingDB. Target information contains target name, target 
source organism and drugs binding affinity data (such 
as Ki, IC50 and Kd) with reference to the original publica-
tion. The chemical structures are stored in the database 
using the IUPAC international chemical identifier (InChi 
key and InChi code) and SMILES (simplified molecular-
input line-entry system). Drug structures were checked 
for potential problems (incorrect structures, salts) and 
then normalized in the database using their InChi key 
to avoid duplicate entries. For each compound, external 
reference to DrugBank, PubChem, IUPHAR and ChEBI 
were added in order to facilitate cross-linking and cross 
checking. The overall flowchart depicting the different 
steps of the database construction with sources, contents 
and processes is presented in Additional file 1.
Database design
IDAAPM is designed as an object-relational database, 
which is implemented in the Postgresql database server. 
A summarized model of the relational database struc-
ture is shown in Fig.  1. The overall detailed model and 
documentation are available in Additional files 2 and 3. 
The IDAAPM model is centered on products, adverse 
effects, drug structures, and targets tables. The first step 
of designing IDAAPM was to link approved drug infor-
mation from FDA to chemical structures, targets and 
corresponding binding affinities. Then, for each drug 
molecule, molecular descriptors, ADMET and adverse 
effects data were extracted and filled. Identifying entities 
(main groups of information) and how they are related 
together were the most important step in the IDAAPM 
design. The last step was to normalize the database 
model, which allowed us to remove redundant informa-
tion. This allows the database model to be flexible and 
reliable during maintenance, as well as to propagate to 
the entire database each update.
Data preparation and integration
Data in IDAAPM was extracted from the resources listed 
above and supplemented with journal references when 
available (Additional file 1). First, all FDA approved drugs 
data were downloaded from Drug@FDA database in text 
file. Second, a .sql script (Additional file 4) was developed 
to extract and insert them in IDAAPM. The FAERS data-
base was downloaded entirely into an .xml file, then an 
R script (Additional file 5) was developed to extract the 
adverse effects data of all approved drugs. Following this, 
a .sql script (Additional file  6) was written to insert the 
data into the IDAAPM database. Next, approved drugs 
data were downloaded from DrugBank into an .xml file, 
Fig. 1 Simplified entity-relational model of IDAAPM. Eight entities or tables (main group of data) are shown linked by different types of association 
(see legend) to characterize how they are related to one another
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extracted with an R script (Additional file 7) and inserted 
into IDAAPM using a .sql script (Additional file  8). 
Then, PubChem and ChemIDplus were used to manu-
ally extract about 50 compound structures and molecu-
lar properties missing from DrugBank data. After that, 
drug-targets bioactivity data were downloaded from 
BindingDB as a .tsv file. A .sql script (Additional file  9) 
was developed to extract and insert the corresponding 
chemical structures, molecular descriptors, ADMET 
property information, drug target information and bind-
ing affinity as well as available literature references into 
IDAAPM. The SMILES and InChI code were cross-
compared to those reported in PubChem and ChEMBL 
as an additional means to check for errors. Moreover, 
links to popular databases were also captured, if available. 
The curating process involved reading scientific articles 
(abstracts and full texts) then checking data to ensure 
that the correct drug names and affinity data had been 
assigned, followed by then manually cross checking the 
accuracy of data between different sources. A KNIME 
workflow module was developed to cross check the drug-
target bioactivity data from PubChem and CheMBL. 
Special attention was given to the quality of chemical 
structures and bioactivity data. Finally, manual checking 
was performed on each entry as part of a continuous pro-
cess. The binding affinity data unit of measurement are 
standardized preferred units of measurements for a given 
activity type. For instance, Ki, IC50, Kd EC50 are recorded 
as nM, rather than µM or mM. This enables the user to 
easily compare data across different assays. We ensure 
that all bioactivity data in the database has been refer-
enced. If a user finds a specific compound to be useful, 
they may follow the links to view literature available on 
that compound. Protein targets are further classified as 
receptor, enzyme, transporter, channel, kinase and oth-
ers. This also allows data to be queried at a higher level.
Current contents
A summary of the database content is shown in Table 1 
(Additional file 10), which present the statistic of current 
IDAAPM database and their sources. IDAAPM is catego-
rized into four major groups: (1) Approved drugs infor-
mation, structure and physico-chemical properties; (2) 
ADMET properties; (3) Adverse effects; (4) Target and 
affinity data. The targets are defined by their Uniprot 
information (identification number and name) as well 
as the 3 letters PDB code when available. About 1629 
FDA approved drug structures were collected, approxi-
matively the amount present in most popular chemical 
databases (PubChem, DrugBank, GtoPdb and ChEBI). 
Adverse effects are the most populated at about 97  % 
(2.5 million) of the overall database, then the remain-
ing data are drugs-targets affinity and FDA approved 
drug applications, as well as their related structural and 
physicochemical data. Figure  2a shows the composition 
of the database by mode of administration and drugs sta-
tus information. There are a total of 20 prescription drug 
areas covered by the database, such as gastrointestinal, 
cardiovascular, diabetes and endocrinology, immune sys-
tem, hematology, eye, cancer and so on. These prescrip-
tion drug area classifications are collected from FDA 
definitions of a new drug approval or a new molecular 
entity. Figure 2b shows the distribution of the main tar-
get classes and drugs by therapeutic area. Adverse effects 
were grouped in 26 main SOC MedDRA terms; Fig.  3a 
shows their frequency and drugs by therapeutic areas.  
KNIME workflows
KNIME is one of the most popular open-source pro-
grams in the field of chemoinformatics and bioinfor-
matics. The KNIME analytics platform integrates tools 
for data preprocessing and cleaning, analysis, and mod-
eling. Moreover, it contains data mining modules (Mat-
lab, Weka, R) as well as interactive view environments 
and additional plugins allowing computational chemis-
try to be run. The platform offers access to a vast library 
of statistical routines and numerous libraries created by 
the scientific community and commercial software ven-
dors. KNIME workflows were developed to allow access 
and query IDAAPM (Fig. 4a). These workflows include a 
Table 1 Summary of IDAAPM content
FDA applications Products Active  
ingredients
Structures Drug  
areas
Target 
classes
Adeverse 
effects
Targets Drug–targets 
interactions
14,260 Generics
4849 New drugs
117 Biologics
Total: 19,226
31,815 2505 1629 20 6 2,472,329 3382 36,963
(See figure on next page.) 
Fig. 2 a Composition of IDAAPM drugs by mode of administration. Each histogram bar represents the amount of drugs present in IDAAPM for a 
selected mode of administration and is colored by commercial status of the drug. b Target distribution in IDAAPM by protein family. Each histogram 
bar represents the amount of target present in IDAAPM for the five most populated protein classes and is colored by their corresponding drug area
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series of constructive extraction, analysis, visualizing and 
computational steps (Fig. 4b–d). All the needed libraries 
have been integrated into the KNIME environment for 
that purpose.
Utility
Database access
IDAAPM is freely accessible via an online graphical 
user interface at (http://idaapm.helsinki.fi). The data-
base browser was organized using a flask framework, 
java script, cascading style sheet and Jinja2 applications 
(Additional file 11A). The IDAAPM server was built with 
gunicorn, nginx and PostgreSQL 9.3.12, installed on 
Ubuntu 14.04.4. The user interface allows users to search 
the database by drug area, route of administration, tar-
get class, small molecules or biologics. Search with one 
of the above criteria allows retrieval of all matching drugs 
with their approval information, molecular descriptors, 
2D structures, targets (Additional file  11B) and related 
bioactivity as well as adverse effect frequency and links to 
the literature references from which the data originated 
(Additional file  11C). From the download page, users 
can download the entire database as TSV/CSV format 
or a specific subset (small molecules/biologics) as well as 
molecular structures (SMILES format). A database dump 
is also available for download enabling users to install 
their own local copy of the database.
Finally, and most importantly, IDAAPM can be 
exploited through KNIME workflows (can be downloded 
from http://idaapm.helsinki.fi) connected to the database. 
The KNIME access (Fig.  4a) workflow enables the data-
base to be queried by drug name, active ingredient, FDA 
application number, SMILES, sub-structural and struc-
tural similarity search (Additional file 12). The user has the 
possibility to build complex queries to search the database. 
IDAAPM provides different levels of ADMET properties 
and adverse effects search. At the first level, the search can 
be performed by (1) choosing to view all drug information, 
(2) searching a specific compound using drug name or 
active ingredient or (3) compound searching by drug area. 
At the second level, searching can be performed using 
drug area, route of administration and drug target class 
to further filter the results. More specific searches can 
also be performed using FDA application number, brand 
name, and active ingredient or drug area. Similarly, results 
obtained can be later exported as .sdf files (Fig. 4b). Com-
pound searching can be filtered by drug area as well, such 
as gastrointestinal, Cardiovascular, Diabetes Drugs and 
Endocrinology, Eye, Hematology and so on. At the lowest 
level, the search criteria set up in the two previous levels 
can be completed with more additional data, using the 
check boxes in the last section (Additional file 12).
Database usage
Clean, structured and high quality data stored in a rela-
tional database resource can facilitate computational pre-
dictive modeling, thus allowing for new information to 
be inferred by computational analyses. Data mining using 
resources like IDAAPM can be employed to understand, 
for example, target function or the promiscuous nature of 
compounds binding to specific types of proteins. We can 
infer the relationships between targets and their drugs in 
order to characterize the molecular properties of com-
pounds with specific ADMET properties and adverse 
effects. For a new compound or target, IDAAPM can be 
exploited in regard to probable mode of administration 
and status (Fig. 2a), target class and drug area (Fig. 2b) as 
well as adverse effect and the drug area of current drugs 
in the database (Fig. 3a).
IDAAPM enables researchers to perform data analysis 
and data mining from safe drugs data and to identify the 
space of similar compounds and similar targets. This is 
particularly important for prediction of possible ADMET 
properties or adverse effects of new drug molecules. 
Furthermore, this will allow the prospect of in silico 
approaches to be used for drug repurposing through the 
integration of knowledge from IDAAPM.
Three examples of usage are presented. In the first 
example, IDAAPM usage coupled with KNIME capabili-
ties is presented in Fig. 4c, d. First, on Fig. 4c, for a set 
of compounds selected from IDAAPM, a distance matrix 
can be calculated and used to characterize the chemical 
space (heat map and 2D/3D scatter plot) as well as clus-
ter analysis (hierarchical clustering) of the compounds 
selected by querying IDAAPM (Fig. 4c). Then, on Fig. 4d, 
a structure similarity towards IDAAPM compounds is 
exemplified to identify the most similar or dissimilar 
compounds using for example Tanimoto similarity coef-
ficient (Fig. 4d). As a result, a 2D/3D structural similarity 
matrix is obtained by computing Tanimoto distance val-
ues for all pairs of the compounds, included as a single 
column containing distance vector values.
In the second example, data mining on IDAAPM is 
demonstrated in the context of ocular pharmaceutics. 
Firstly, adverse effects are mined to identify the most 
frequent adverse effects for ocular drugs and their rela-
tive frequency (see Fig.  5). This can be combined with, 
for example ocular adverse effects for systemic drugs 
(see Fig. 3b). The data can be analyzed to connect drugs, 
drug targets and their adverse effects, delivering a pow-
erful data mining approach for example to better under-
stand polypharmacology or to predict ocular side effects. 
This is particularly important for prediction of possible 
adverse effects of new drug molecules. Furthermore, 
this will allow the prospect of in silico approaches being 
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Fig. 3 a Frequency of adverse effects. For the 26 adverse effects SOC MedDRA terms, each histogram bar corresponds to the amount of the 
selected adverse effect in IDAAPM and is colored by their corresponding drug area. b Systemic drugs distribution with ocular adverse effects. 
Adverse effects reported have relative frequency >0.1, each histogram bar corresponds to the primary area of systemic drugs with ocular adverse 
effect and is colored by their route of administration
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utilized for drug repurposing through the integration of 
knowledge from IDAAPM.
A third example of usage is provided by a work-
flow (in Fig.  4e) used to build predictive classification 
models inside KNIME from bioactivity data, ADMET, 
adverse effects, or molecular descriptors selected from 
IDAAPM is demonstrated. Data are uploaded from .sdf 
files exported from a search result made on IDAAPM. As 
seen in this example, the data are first normalized, then 
separated into training and test sets. This is followed by 
model construction, either using K-nearest neighbors or 
the support vector machine method. The stability of the 
trained model can be verified through cross validation 
during the process and its predictive ability can be esti-
mated using the external test set. The scorer node reports 
a confusion matrix and the related accuracy statistic of 
generated models.
Conclusion
IDAAPM offers structured and manually curated data on 
approved drugs, physicochemical properties, ADMET 
and adverse effects as well as related target informa-
tion. It provides measured bioactivities, also structural 
information, which is essential in predictive modeling. 
IDAAPM combines detailed information on approved 
drugs in a single platform integrated with KNIME. The 
KNIME workflow has been developed to allow for easy 
access to the safe compound information and further 
provide the researcher with more opportunity to develop 
their own custom workflow, depending on their needs. 
Fig. 4 IDAAPM utility examples. Examples of KNIME workflows to access IDAAPM (a), export data (b), make preliminary analysis (c, d) and build 
predictive classification models (e)
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The availability of the data in an easily accessible form 
will allow researchers in the field to easily use this data 
as well as allow easy integration with other programs and 
services. It will provide data from available safe drugs and 
knowledge for drug discovery and development.
Further data curation, comprehensive data coverage 
and improvements are planned for subsequent IDAAPM 
releases, as well as inclusion of additional predictive 
modeling KNIME workflows. Moreover, we aim to 
include all compounds in advanced clinical trials, as this 
is highly relevant in the context of drug discovery. Even 
though the first release of IDAAPM includes experimen-
tal and calculated physico-chemical properties, we aim to 
include additional molecular properties.
Fig. 5 Ocular pharmaceutics adverse effect network with relative frequency >0.1. Adverse effects are reported using the system organ class of the 
medical dictionary for regulatory activities
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Availability
IDAAPM full database and KNIME workflows are freely 
accessible at http://idaapm.helsinki.fi.
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